Connor, Clark & Lunn Investment Management (CC&L)
BPMC

Connor, Clark & Lunn Investment Management (CC&L)’s Blueprint Medicines BPMC Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-183,947
Closed -$16.3M – 1518
2025
Q1 		$16.3M Buy
183,947
+41,230
+29% +$4.02M 0.07% 228
2024
Q4 		$12.4M Buy
142,717
+137,585
+2,681% +$12.6M 0.06% 270
2024
Q3 		$475K Buy
+5,132
New +$510K ﹤0.01% 1110
2024
Q1 		– Sell
-6,472
Closed -$597K – 1532
2023
Q4 		$597K Buy
+6,472
New +$419K ﹤0.01% 995
2023
Q3 		– Sell
-12,994
Closed -$821K – 1374
2023
Q2 		$821K Sell
12,994
-10,724
-45% -$583K ﹤0.01% 858
2023
Q1 		$1.07M Buy
23,718
+9,265
+64% +$417K 0.01% 693
2022
Q4 		$633K Buy
14,453
+10,855
+302% +$521K ﹤0.01% 814
2022
Q3 		$237K Buy
+3,598
New +$231K ﹤0.01% 962
2021
Q1 		– Sell
-9,525
Closed -$1.07M – 990
2020
Q4 		$1.07M Buy
+9,525
New +$1M 0.01% 621

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s BPMC Position: Q2 2025 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 183,947 shares — an estimated $16.3M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in BPMC in Q4 2020 and held it in 9 quarters. The position peaked at $16.3M in Q1 2025. 355 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 183,947 Blueprint Medicines shares in Q2 2025, an estimated $16.3M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Blueprint Medicines in Q4 2020 and held it in 9 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Blueprint Medicines position peaked at $16.3M in Q1 2025.
  • 355 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2025, filed 7 Aug 2025.